GSA Capital Partners LLP Takes Position in Personalis, Inc. $PSNL

GSA Capital Partners LLP bought a new stake in shares of Personalis, Inc. (NASDAQ:PSNL) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 43,244 shares of the company’s stock, valued at approximately $579,000.

Several other institutional investors have also bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its holdings in Personalis by 8.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,066,248 shares of the company’s stock worth $6,791,000 after acquiring an additional 83,074 shares during the last quarter. Sei Investments Co. raised its holdings in shares of Personalis by 148.3% in the first quarter. Sei Investments Co. now owns 139,046 shares of the company’s stock valued at $886,000 after purchasing an additional 83,040 shares during the last quarter. Howland Capital Management LLC raised its holdings in shares of Personalis by 65.5% in the fourth quarter. Howland Capital Management LLC now owns 547,115 shares of the company’s stock valued at $4,355,000 after purchasing an additional 216,442 shares during the last quarter. Next Century Growth Investors LLC bought a new position in shares of Personalis during the fourth quarter valued at about $4,970,000. Finally, D.A. Davidson & CO. bought a new position in shares of Personalis during the fourth quarter valued at about $1,158,000. Institutional investors own 61.91% of the company’s stock.

Insider Activity

In other Personalis news, CFO Aaron Tachibana sold 4,982 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $14.00, for a total value of $69,748.00. Following the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at $2,783,662. The trade was a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the transaction, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $3,558,668.88. This represents a 29.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 435,032 shares of company stock worth $5,599,929. Insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. TD Cowen reaffirmed a “buy” rating on shares of Personalis in a research report on Wednesday, July 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research report on Friday, July 17th. Zacks Research cut shares of Personalis from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 21st. Needham & Company LLC downgraded Personalis from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Finally, Lake Street Capital lowered Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price for the company. in a report on Monday, July 20th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $14.25.

Personalis Price Performance

NASDAQ PSNL opened at $16.88 on Friday. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of -15.49 and a beta of 2.27. Personalis, Inc. has a one year low of $4.59 and a one year high of $17.06. The business’s fifty day moving average is $13.12 and its 200-day moving average is $9.62.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The company had revenue of $22.36 million for the quarter, compared to the consensus estimate of $16.69 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. Research analysts expect that Personalis, Inc. will post -1.07 EPS for the current fiscal year.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.